Achieve Life Sciences: Nearing Commercialization of Cytisinicline for Smoking and E-Cigarette Cessation.

Achieve Life Sciences is a pre-commercial pharmaceutical company developing cytisinicline for smoking and e-cigarette cessation. The company recently announced a New Drug Application (NDA) submission based on positive data from a Phase 2b trial. The trial demonstrated that cytisinicline was effective in reducing nicotine cravings and improving smoking cessation rates. Achieve Life Sciences is nearing commercialization of its best-in-class pharmaceutical product for smoking cessation.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) has made significant strides in the development and commercialization of cytisinicline, a promising drug for smoking and e-cigarette cessation. The company recently submitted a New Drug Application (NDA) for cytisinicline, marking a pivotal milestone in its journey to bring this innovative product to market. The submission, based on positive data from a Phase 2b trial, demonstrates cytisinicline's effectiveness in reducing nicotine cravings and enhancing smoking cessation rates.

Achieve Life Sciences has been working on cytisinicline for over a decade, with the primary goal of developing a more effective alternative to existing smoking cessation treatments. The drug, a derivative of cytisine, a naturally occurring plant-based substance, has shown significant promise in clinical trials. Achieve Life Sciences has acquired the rights to cytisine outside of Sopharma's territories, securing an exclusive license and supply agreement with the company, up to 2037. The company also owes royalty payments to Sopharma and the University of Bristol.

The NDA submission is a critical step in the regulatory process. If the FDA accepts the submission, the agency will review the data and make a decision on approval within 12 months. Achieve Life Sciences expects to see the FDA formally accept the NDA by late August and is preparing for the sales effort that will follow. The company has outlined a comprehensive commercialization strategy and has partnered with Omnicom Group to execute the plan. Omnicom's expertise in brand and advertising services, combined with its digital transformation capabilities, will help Achieve Life Sciences precisely target and engage healthcare professionals and patients.

In addition to the NDA submission, Achieve Life Sciences has also closed a $45 million capital raise, which will support the company's ongoing research and development efforts. The capital raise, completed on June 30, 2025, involved the issuance of 15 million shares at $3.00 each, with an attached warrant exercisable at $3.00 per share. The company also issued approximately 16.8 million warrants upon the partial exercise by the underwriters of their option to purchase additional shares. Net proceeds from the capital raise are estimated to be $41.3 million.

Achieve Life Sciences is also advancing its safety data collection efforts. The company has completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial, with no safety concerns identified by the Data Safety Monitoring Committee (DSMC). As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment, with about 75% of participants remaining on treatment. This suggests that cytisinicline is well-tolerated, which is particularly notable given the high discontinuation rates for existing smoking cessation products like Chantix.

Looking ahead, Achieve Life Sciences plans to complete the one-year safety data package in the next few months and submit it to the FDA by the 120-day safety review milestone, expected to be around year-end 2025. The company also expects to launch a Phase III vaping trial in the first half of 2026. If the FDA approves cytisinicline, the company plans to launch the product in the third quarter of 2026.

In summary, Achieve Life Sciences is making significant progress in the development and commercialization of cytisinicline. The company's NDA submission, capital raise, and safety data collection efforts position it well for a successful launch of the drug. Investors and financial professionals should closely monitor Achieve Life Sciences' progress as it nears commercialization of its best-in-class pharmaceutical product for smoking cessation.

References:
[1] https://finance.yahoo.com/news/achv-achieve-busy-day-091600759.html
[2] https://seekingalpha.com/article/4799715-achieve-life-sciences-nearing-commercialization-of-smoking-cessation-product